Report of the 43rd Meeting of the TDR Scientific and Technical Advisory Committee – STAC43

17-18 March 2021

Introduction

The forty-third meeting of the Scientific and Technical Advisory Committee (STAC) of the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) took place virtually on 17 and 18 March 2021. The meeting was chaired by Professor Stephen Bertel Squire, standing in for Professor Charles Mgone, who was unable to attend due to an accident. The meeting was attended by STAC members and the TDR secretariat (refer to the list of participants for a full list of attendees).

Summary of proceedings

AGENDA ITEM 1 – Opening of the meeting

Key messages

Professor Squire welcomed STAC members to the second virtual meeting of STAC, acknowledged their significant contribution to the work of TDR and invited members to provide good scientific advice that will move TDR’s portfolio of projects forward. He reminded STAC members of their role: to advise on planning and implementation and to give guidance on prioritization and strategy within TDR, and gave his best wishes for a productive meeting.

Professor Squire welcomed three new STAC members: Professor Mirkuzie Kerie, Senior Research Adviser at the Federal Ministry of Health in Ethiopia; Dr Caroline Lynch, Regional Adviser for Medicines for Malaria Venture in Thailand; and Dr Emelda Okiro, Head of the Population Health Unit of the KEMRI/Wellcome Trust Collaborative Programme in Kenya. He also mentioned that Dr Catharina Boehme had withdrawn her membership as she has moved to a senior position in WHO.

Professor John Reeder, Director TDR, highlighted the overall focus of the meeting on informing the scientific and technical priorities in the work that will be done in 2021–2023, and thanked STAC members for their participation.
Dr Soumya Swaminathan, WHO Chief Scientist and TDR Special Programme Coordinator, welcomed participants and provided an update on the activities of the Science Division, both in supporting the COVID-19 global response and to designing and implementing a strategic plan for the Division. She presented examples of TDR’s collaboration with other entities in the Division, as well as future themes where TDR could contribute its expertise and knowledge, such as strengthening country capacity for health research, research ethics, a framework for sharing research data as a global public health good, etc.

AGENDA ITEM 2 – Statutory business

Professor Squire proposed that Professor Afif Ben Salah be appointed Rapporteur of STAC43. Professor Ben Salah was appointed Rapporteur by acclamation.

A call was issued for any conflicts of interest. No conflicts were declared, however Acting Chair STAC invited any members who may have a specific conflict of interest for an agenda item to voice that accordingly.

Decisions:

• Professor Afif Ben Salah was appointed Rapporteur of STAC43.
• The Agenda of STAC43 was adopted as proposed.
• Declarations of interests were accepted as presented to the Secretariat, with no conflicts foreseen.

AGENDA ITEM 3 – Director’s Report and follow-up on STAC42 recommendations

Key messages

Professor Reeder’s presentation highlighted some of TDR’s key achievements in 2020, as well as challenges and opportunities faced by the Programme during the COVID-19 pandemic. Progress made on some expected results was presented in more depth, and participants were invited to study the interactive TDR Annual Report for more details on TDR achievements.

Key achievements from 2020 in research for implementation were mentioned, among which:

• Supporting implementation research to mitigate the impact of COVID-19 on TB and malaria control in Africa.
• New toolkits to support country-led implementation research, such as scaling up digital technologies for TB care and supporting scientists to incorporate intersectional gender analysis into their research.
• Guidance developed for implementing a multisectoral approach to disease control through vector control.
• A global directory of medical entomology courses published online.
• Operational research to accelerate universal health coverage: high-quality evidence generated through the SORT IT approach, and an innovative virtual platform developed for online training courses.
Priorities for 2021 in the research for implementation strategic priority area were presented:

- Supporting national disease programmes to overcome COVID-19 challenges.
- Community engagement, coverage of hard-to-reach populations.
- Multisectoral approach and operationalizing One Health for the control of vector-borne diseases (VBDs).
- Gender mainstreaming – implementation research with an intersectional gender lens.
- SORT IT – with virtual platform, conduct courses in francophone Africa, supporting new hubs.

Key achievements from 2020 in research capacity strengthening were outlined, among which:

- Adapting training programmes to the COVID-19 pandemic: the Postgraduate Training Scheme, the Clinical Research and Development Fellowship scheme and the Regional Training Centres have all adapted their courses to continue remotely and through online / virtual training.
- Professor Reeder highlighted the role of the Research Capacity Strengthening programmes in building health system resilience to the pandemic; this was proven by surveys which showed that between 73% and 91% of trainees applied skills learned from TDR training to their COVID-19 response activities.
- Improved training opportunities for French-speaking researchers through a dedicated French-speaking West Africa hub in the Postgraduate Training Scheme, establishment of a sub-regional training centre; development of a SORT IT programme for French-speaking researchers; a MOOC on implementation research developed in English, French and Spanish, etc.

Priorities for 2021 in the research capacity strengthening strategic priority area were presented:

- Focus on intensifying efforts to promote virtual training tools to increase reach and impact.
- Implement activities with increased funding under the revised TDR budget scenario.
- Postgraduate Training Scheme transition to phase 2: call in Q1 of 2021 for applications to select participating universities.
- Transition from the Clinical Research Development Fellowship scheme (CRDF) to the Clinical Research Leadership Programme (if designated funding is confirmed).
- ADP\(^1\) activities expanded to cover more countries and focus on virtual training.

Key achievements from 2020 in global engagement were enumerated, among which:

- Social Innovation in Health Initiative (SIHI) partnered with the WHO Health Emergencies Programme on a community engagement package.
- Forty-eight (48) research grants awarded across the six WHO regions though the small grants scheme.
- TDR Global initiative on innovative financing for research led to a successful crowdfunding campaign.
- TDR joined the COVID-19 Clinical Research Coalition to contribute to the data sharing agenda.
- TDR’s toolkit for incorporating intersectional gender analysis into research on infectious diseases of poverty was launched in October 2020, aligned with TDR’s intersectional gender research strategy.

\(^1\) The Access and Delivery Partnership
Training courses on gender-based analysis of VBDs and climate change were implemented in Ghana and South Africa.

New Podcast: Global Health Matters explores how innovative and inspiring research contributes to achieving health for all.

Priorities for 2021 in the global engagement strategic priority area were presented:

- SIHI and TDR Global continue to expand in WHO regions.
- Small grants partnerships to focus on migration and health, as well as International Health Regulations implementation.
- Continue support for data-sharing initiatives (IDDO and others).
- Continue to strengthen and increase TDR’s leadership in gender and infectious disease research among funders, academia and research and training partners.

Discussion points:

- STAC commended the secretariat for the excellent work conducted in 2020, under challenging conditions, managing to deliver results and transform training approaches to adapt to the new health emergency conditions.
- The SORT IT approach has gained a good reputation among researchers in countries for bringing people from ministries of health, WHO country offices and researchers in academia.
- The role of data management in research, technology and intellectual property was discussed as a potential area where TDR could contribute.

Decision:

- Endorsed the Director’s report and congratulated the Programme on its extraordinary achievements during the past year.

STAC comments:

- Congratulated TDR’s Director and staff on the remarkable achievements and hard work done in 2020, and to date in 2021, despite the difficult global situation with the COVID-19 pandemic.
- Welcomed TDR’s flexibility in adapting during the pandemic by engaging in supporting COVID-19 initiatives, providing virtual capacity building opportunities and engaging globally with key partners.

AGENDA ITEM 4 – Programme performance overview

Preliminary financial report for 2020 and outlook for 2021-2023, progress made against TDR key performance indicators and progress on the implementation of TDR’s risk management plan – presented by Dr Beatrice Halpaap, Unit Head, TDR Programme Innovation and Management

Key messages:

- The TDR Performance Framework, aligned with TDR’s Strategy 2018–2023, guides TDR’s work and defines the way TDR measures success in technical achievements, application of core values and management performance.
- The 26 Programme-level key performance indicators help monitor and evaluate TDR’s results against the planned targets, as reflected in the 2020 Results Report.
• At 31 December 2020, 22 of the 23 Expected Results were on track to deliver their outputs. One was delayed.

• Countries, as well as global and regional institutions, have been using TDR outputs, translating these solutions into policies, practice and new approaches. Forty-three (43) instances of outputs utilized in countries and six instances of use by global or regional institutions were enumerated.

Financial implementation:

• A financial overview was presented by Dr Halpaap, based on the Preliminary Financial Report 2020 and Outlook 2021-2023 document which was made available to STAC.

• The 2020-2021 Programme budget and workplan scenarios were approved by the TDR Joint Coordinating Board (JCB) in 2019. Approximately 80% of funds for operations and 20% for operational support are allocated in each of the two scenarios, US$ 40 million and US$ 50 million.

• Income forecast can be significantly affected by exchange rates. TDR’s forecast is conservative and takes into consideration risks arising both from exchange rates and changes in the level of contribution. As part of the budget cycle, revision of the planned cost to US$ 44 million (based on available and forecasted funds) was explained, in line with the JCB-approved budget and workplan.

• The financial implementation rate at 31 December 2020 was 41%, while at 28 February 2021 it reached 50%, reflecting an acceleration of the pace as the biennium advanced.

• Detailed tables by expected result, strategic priority area and type of funding were presented.

Risk management:

• The current status of Programme-level risks was presented, together with a brief explanation of action items which are explained in full in the 2020 Risk Management Report.

• At end 2020, there were six risks that were ongoing with mitigation actions on track (one of them proposed for closure in 2021); three risks are having minor issues and being closely monitored, while one continues to have major issues (WHO staff mobility policy).

Application of core values:

• In 2020, TDR made progress on a number of indicators measuring the Programme’s focus on low- and middle-income disease-endemic countries (DECs), including gender equity and open access.

• The proportion of contracts awarded to DEC institutions and individuals (measured by US dollar amount), the proportion of first, last and corresponding authors of TDR-supported publications from DEC institutions, and the proportion of advisers from DECs, have improved and were around or even well above the respective targets.

• Indicators for gender equity continued to improve on the same positive trend recorded in previous years. The secretariat is analysing the data following STAC42’s recommendation, and will produce a report in an attempt to identify factors leading to the improvement.

• A question was addressed to STAC regarding how to collect and report expanded data on gender, while continuing to focus on the empowerment of women and at the same time keeping Principal Investigators safe in their countries (some of which may have strong stigma and oppression of people with non-binary gender identification).
2022–2023 revenue forecast and budget scenarios:

- Two budget scenario levels for the 2022–2023 biennium were approved by JCB in 2020, at US$ 40 million and US$ 50 million for the lower and higher budget scenario respectively.
- The split by operations versus operations support and between the various strategic work areas was presented and explained, as well as the income forecast for 2022–2023.

Discussion points:

- WHO’s mobility policy and its potential impact on TDR results was discussed, as well as the importance of seeking the best solution to maintain the Programme’s specialized and specific staff expertise and competitiveness.
- The adoption of TDR outputs and utilization in countries, regions and globally was discussed, together with ways to collect utilization information from grassroots and feed it back into the Programme.
- Regarding collection and reporting on gender data, the discussion highlighted the need to consult with other Programmes, researchers in countries and other stakeholders on the best ways to collect and handle sensitive data.

Decisions:

STAC endorsed the following documents:

- Preliminary 2020 Financial Report and Outlook 2021−2023
- 2020 Results Report
- 2020 Risk Management Report

Recommendations:

- Welcomed TDR’s efforts to ensure gender inclusivity in its activities while safeguarding confidentiality. Recommended that TDR engage in consultations with WHO, other funders and partners in countries, to further develop an approach to gender data collection, confidentiality and M&E indicators.

AGENDA ITEM 5 – Update from Chairs of Scientific Working Groups

Research for Implementation – presented by Professor Bertie Squire

- Professor Squire presented highlights of the meeting and recommendations of the IMP SWG in 2020.
- The SWG reviewed the membership expertise matrix and proposed that in 2021 the group would be co-chaired by Professor Squire and Professor Sassy Molyneux.
- Recommended greater synergy between the units on the topics of gender and One Health.

Research Capacity Strengthening – presented by Dr Alwyn Mwinga

- Dr Mwinga briefed the STAC on the RCS SWG recommendations from 2020.
- Moving towards the second phase of the Postgraduate Training Scheme in 2021.
- Exploring taking the CRDF scheme to the next level to further build leadership in DECs.
AGENDA ITEM 6 – Report on technical progress in 2020 and planned activities for 2021-2023

Global Engagement – presented by Dr Garry Aslanyan, TDR Partnerships and Governance Manager

Key messages

- The SIHI Secretariat, based at the University of the Philippines, Manila, is coordinating and leveraging resources, including a grant from the WHO Health Emergencies Programme. Expansion in 2020 to new countries and leveraging significant resources in countries.
- TDR Global innovative financing: First success of a crowdfunding challenge for health research.
- New Discovery platform for TDR Global enhanced to find and make direct contact with mentors, research experts or collaborators by searching by the name, keyword or discipline.
- Promoting gender responsive interventions on infectious diseases: Developing a new module on gender and intersectionality for the Massive Open Online Course (MOOC) on Implementation Research; TDR’s toolkit for incorporating intersectional gender analysis in research on infectious diseases of poverty; TDR’s intersectional gender research strategy – launched in 2020.
- Knowledge management: Shaping the research agenda 2020. Global R&D for neglected diseases portfolio analysis (P2I – Portfolio to Impact) – WHO Global Public Good, new analysis published; 25 articles now on TDR Gateway; TDR led the development of a new guide for WHO staff undertaking research priority setting.
- Data-sharing infrastructure, governance and capacity on the following diseases: Malaria, Schistosomiasis, HAT plus Zika, Ebola Data Platform and COVID-19.
- Collaborating with WHO and other partners on small research grants: Adapting to COVID-19 calls reflect new needs and focus on new priorities; collaboration with new partners and players to promote IR, including WHO’s Health and Migration Programme, regional disease elimination plans and implementation of the International Health Regulations. Leveraged US$ 1 million.
- ESSENCE – harmonizing investments in research: Engagement of new funders from high-income countries as well as LMICs, e.g. India Alliance and the African Academy of Sciences.

Discussion points:

- Discussed the type of evidence for translation to policy and practice, and the type of analysis and evaluation that was done for SORT IT, as well as the possibility to explore grey literature to capture such evidence in the future.

AGENDA ITEM 7 – Reports on technical progress in 2020 and planned activities for 2021-2023

Research for Implementation (IMP) – presented by Dr Abraham Aseffa, Unit Head

Key messages

- Updates on activities and achievements across the four workstreams were presented.
- Early Warning and Response System (EWARS) for arbovirus outbreaks implemented in fourteen countries.
- Country capacities for arboviral disease surveillance, control and outbreak preparedness: Capacities of seven countries have been strengthened for improving entomological surveillance.
- Global aDSM database used for informing guidelines. Discussion ongoing with WHO pharmacovigilance department for a handover of safety databases that TDR currently hosts.
- WARN-TB/CARN-TB research activities: 40 ongoing OR/IR projects, focused on vulnerable and marginalized populations.
- TDR supports 25 countries implementing the ShORRT research package.
- e-health technology for improving TB care and TDR contribution was explained.
- Leveraged €3.42 million from EDCTP, Luxembourg and MDGH (not-for-profit sponsor of moxidectin) for development of paediatric moxidectin formulation.
- Visceral leishmaniasis elimination: Exploring lessons for other regional foci such as Eastern Africa.
- Pilot testing the framework for operationalizing One Health as a transdisciplinary ecosystem approach in five African countries.
- Multisectoral approaches to prevent and control vector-borne diseases case studies implemented in 2021 to test the theoretical framework.
- Innovative vector control tools: Online directory of courses in medical entomology was launched.
- Development of case studies focusing on schistosomiasis, tuberculosis and lymphatic filariasis with an intersectional gender lens.
- AMR SORT IT: A virtual SORT IT platform for training was created as an alternative means of continuing training despite COVID-19-related restrictions.

Discussion points:
- Commended the work of the unit.
- Discussed the antimicrobial resistance potentially being impacted by the COVID-19 pandemic and use of various antimicrobials massively at scale.
- How the COVID-19 pandemic may delay some activities by diverting resources and also by prioritizing the approval of pandemic-related projects by ethics review committees, while sidelining other research projects.
- How to use digital tools and technology advances gained during the COVID-19 pandemic to improve access for vulnerable populations through digital technologies. How to combat disinformation while engaging communities in research.
- Reduced TB detection during the pandemic is likely to lead to an increase in cases in the coming years – how can TDR help with case detection?
- Pharmacovigilance templates adapted for COVID-19 vaccination side-effect reporting – could be linked to the moxidectin side-effect reporting in onchocerciasis
- The ShORRT Operational Research Package for roll-out of the shortened all-oral MDR regimen as an example of an OR package that paves the way for adapted approaches for other regimens.
Research Capacity Strengthening (RCS) – presented by Dr Dermot Maher, Unit Head

Key messages

• Dr Maher spoke about ways in which TDR helped countries build resilience to the COVID-19 pandemic through capacity strengthening over the last years and decades.
• The RCS team adapted to COVID-19 through remote working and continued to deliver activities to strengthen capacity for research, with a focus on virtual training.
• Achievements in multilingualism of TDR grants and training schemes and a focus on increased gender equity in 2020.
• COVID adaptation: The seven universities part of TDR’s Postgraduate Training Scheme actively adopted virtual trainings to ensure continuation of the scheme with minimal disruption.
• A new module on gender considerations in IR is being developed in line with TDR’s intersectional gender research strategy.
• Following an approach encouraging CRDF applications from women, the percentage of women selected increased from 23% in the previous rounds (2007-2019) to 58.5% in the latest round (2020).
• Postgraduate Training Scheme transition to phase 2: Call in Q1 of 2021 for applications from universities to participate in the scheme.

Discussion points:

• Commended the achievements of the unit.
• Suggested exploring expanding online training courses to reach vulnerable and hard-to-reach populations, even after the end of the pandemic.
• Discussed the added value of TDR facilitating countries to apply for grants from the Global Fund to Fight AIDS, Tuberculosis and Malaria that include operational research.
• Opportunity to explore having more robust blended training tools and approaches during the post-COVID-19 era.
• Qualitative advance from CRDF training scheme to a next-level training scheme for building leadership skills in fellows, as part of re-entry grants.

Decision:

• STAC endorsed the reports on technical progress and planned activities of all strategic priority areas.

Recommendations:

• Recommended exploring the potential for broader application of templates and approaches already developed for specific diseases.
• Recommended that TDR continue to examine and learn from virtual arrangements and consider issues of equity and access by certain groups as it moves forward with virtual technologies.
AGENDA ITEM 8 – Programme budget and workplan 2020-2021
– presented by Dr Beatrice Halpaap

Key messages

• TDR Programme budget scenario levels were approved by the JCB in 2020 at US$ 40 million and US$ 50 million.

• The draft TDR Programme Budget and Workplan 2022–2023 was proposed for comments and recommendations. It presents the expected results, their respective success indicators and budget (split between undesignated and designated funds) for both budget scenarios (US$ 40 million and US$ 50 million).

Discussion points:

• TDR actions on the COVID-19 pandemic are part of various budget items and will be visible at the reporting stage.

Decision:

• Endorsed the TDR Programme Budget and Workplan 2022–2023.

AGENDA ITEM 9 – STAC and SWG Governance
– presented by Dr Garry Aslanyan

Key messages

Membership of both Scientific Working Groups (IMP and RCS) to 31 December 2021 was presented.

Decision:

• Agreed to the membership of the two scientific working groups as presented.

AGENDA ITEM 10 - Date and place of STAC44

Decision:

• Agreed that the forty-fourth meeting of STAC (STAC44) will take place from 16 to 17 March 2022, including a briefing on TDR for new members on 15 March.

Recommendation:

• A mini evaluation of this meeting will be conducted to find out the shortcomings and things which could be improved for future virtual meetings.

Close of STAC43

• Acting Chair STAC thanked members for their hard work in preparation for and during the meeting.
STAC43 summary of decisions and final recommendations

Decisions

1. Professor Afif Ben Salah was appointed Rapporteur of STAC43.
2. The Agenda of STAC43 was adopted as proposed.
3. Declarations of interests were accepted as presented to the Secretariat, with no conflicts foreseen.
4. STAC endorsed the Director’s report and congratulated the Programme on its extraordinary achievements during the past year.
5. STAC endorsed the following documents:
   - 2020 Results Report
   - 2020 Risk Management Report
6. STAC endorsed the reports on technical progress and planned activities of all strategic priority areas
8. Agreed to the membership of the two scientific working groups as presented from 1 January 2021.
9. Agreed that the forty-fourth meeting (STAC44) of STAC will take place on Wednesday, 16 and Thursday, 17 March 2022, including a briefing on TDR for new members on 15 March, if possible, face-to-face.

Recommendations

1. Welcomed TDR’s efforts to ensure gender inclusivity in its activities while safeguarding confidentiality. Recommended that TDR engage in consultations with WHO, other funders and partners in countries, to further develop an approach to gender data collection, confidentiality and M&E indicators.
2. Recommended exploring the potential for broader application of templates and approaches already developed for specific diseases.
3. Recommended that TDR continue to examine and learn from virtual arrangements and consider issues of equity and access by certain groups as it moves forward with virtual technologies.
4. A mini evaluation of this meeting will be conducted to find out the shortcomings and things which could be improved for future virtual meetings.
# Annex 1. Annotated Agenda

**Briefing Session. Tuesday, 16 March (12:00-13:00 CET)**

Introductory meeting about TDR and the STAC being offered to STAC members who wish to acquaint themselves with the Programme and the processes and functions of the Committee. New members are expected to attend, while continuing members are more than welcome to join.

---

## Wednesday, 17 March (12:00-14:30 CET)

<table>
<thead>
<tr>
<th>Time</th>
<th>Item</th>
<th>Topic</th>
<th>Action</th>
<th>Reference documents</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>1.</td>
<td>Opening of the meeting</td>
<td>Dr Soumya Swaminathan, WHO Chief Scientist / TDR Special Programme Coordinator&lt;br&gt;Professor John Reeder, Director, TDR</td>
<td></td>
</tr>
<tr>
<td>12:05</td>
<td>2.</td>
<td>Statutory business</td>
<td>Professor Charles Mgome, Chair STAC&lt;br&gt;2.1 Appointment of the Rapporteur&lt;br&gt;2.2 Adoption of the Agenda&lt;br&gt;2.3 Declaration of interests</td>
<td>Decision&lt;br&gt;Draft Annotated Agenda TDR/STAC43/21.1a</td>
</tr>
<tr>
<td>12:15</td>
<td>3.</td>
<td>Director’s Report and follow-up on STAC42 recommendations</td>
<td>Professor John Reeder&lt;br&gt;20 minute presentation followed by 40 minute discussion</td>
<td>Information and endorsement&lt;br&gt;Report of STAC42 TDR/STAC42/20.3&lt;br&gt;TDR Annual Report 2020&lt;br&gt;Follow-up on STAC recommendations TDR/STAC43/21.4</td>
</tr>
<tr>
<td>14:00</td>
<td>5.</td>
<td>Update from Chairs of Scientific Working Groups</td>
<td>Professor Bertie Squire (Research for implementation)&lt;br&gt;Professor Alwyn Mwinga (Research capacity strengthening)&lt;br&gt;5 min. presentations followed by discussion</td>
<td>Recommendation(s)&lt;br&gt;Note: SWG meeting reports can be found under Item 7.</td>
</tr>
<tr>
<td>14:15</td>
<td>6.</td>
<td>Report on technical progress in 2020 and planned activities for 2021-2023</td>
<td>Global Engagement&lt;br&gt;Dr Garry Aslanyan, TDR Partnerships &amp; Governance Manager&lt;br&gt;10 min presentation followed by 20 min discussion</td>
<td>Recommendation(s)&lt;br&gt;Global Engagement Annual Report 2020&lt;br&gt;Portfolio of Expected Results: 2020-2021 progress and plans for 2022-2023</td>
</tr>
<tr>
<td>Time</td>
<td>Item</td>
<td>Topic</td>
<td>Action</td>
<td>Reference documents</td>
</tr>
<tr>
<td>---------</td>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>12:00–</td>
<td>7</td>
<td>Reports on technical progress in 2020 and planned activities for 2021-2023</td>
<td>Information and recommendation(s)</td>
<td>TDR Expected Results&lt;br&gt;Operational Plans 2020-2021&lt;br&gt;TDR/STAC42/20.9</td>
</tr>
<tr>
<td>12:00</td>
<td>7.1</td>
<td>Research for Implementation (IMP)</td>
<td>Information only:</td>
<td>TDR IMP Annual Report 2020&lt;br&gt;Portfolio of Expected Results: 2020-2021 progress and plans for 2022-2023&lt;br&gt;IMP SWG meeting report</td>
</tr>
<tr>
<td>12:00</td>
<td>7.2</td>
<td>Research Capacity Strengthening (RCS)</td>
<td>Information only:</td>
<td>TDR RCS Annual Report 2020&lt;br&gt;Portfolio of Expected Results: 2020-2021 progress and plans for 2022-2023&lt;br&gt;RCS SWG meeting report</td>
</tr>
<tr>
<td>12:45</td>
<td>7.2</td>
<td>Dr Dermot Maher, Unit Head</td>
<td>15 min presentation followed by 30 min discussion</td>
<td>TDR RCS Annual Report 2020&lt;br&gt;Portfolio of Expected Results: 2020-2021 progress and plans for 2022-2023&lt;br&gt;RCS SWG meeting report</td>
</tr>
<tr>
<td>13:30</td>
<td>8</td>
<td>Programme budget 2022-2023</td>
<td>Recommendation(s) and endorsement</td>
<td>Programme Budget 2022-2023&lt;br&gt;TDR/STAC43/21.8&lt;br&gt;Information only: Portfolio Prioritization Model&lt;br&gt;Refer to Items 4. &amp; 7. for other background documents</td>
</tr>
<tr>
<td>14:00</td>
<td>9</td>
<td>STAC and SWG Governance</td>
<td>Recommendation(s)</td>
<td>List of proposed SWG members&lt;br&gt;TDR/STAC43/21.9&lt;br&gt;TDR’s STAC and scientific working groups: Terms of reference (June 2014)</td>
</tr>
<tr>
<td>14:10</td>
<td>10</td>
<td>Date and place of STAC44</td>
<td>Recommendation(s)</td>
<td>TDR/STAC43/21.8&lt;br&gt;TDR’s STAC and scientific working groups: Terms of reference (June 2014)</td>
</tr>
<tr>
<td>14:20</td>
<td>11</td>
<td>Any other business</td>
<td>Recommendation(s)</td>
<td>TDR/STAC43/21.8&lt;br&gt;TDR’s STAC and scientific working groups: Terms of reference (June 2014)</td>
</tr>
</tbody>
</table>

**CLOSE OF STAC43**
Annex 2. List of participants

STAC Members

(Chair) Professor Charles MGONE*
Vice-Chancellor
Hubert Kairuki Memorial University
Dar es Salaam, United Republic of Tanzania

Professor Afif BEN SALAH
Full Professor of Community Medicine, College of Medicine and Medical Sciences, Department of Community and Family Medicine
Arabian Gulf University
Manama, Kingdom of Bahrain

Professor Claudia CHAMAS
Researcher, Centre for Technological Development in Health
Oswaldo Cruz Foundation (Fiocruz)
Rio de Janeiro, Brazil

Professor Sónia DIAS
Professor, National School of Public Health
Universidade Nova de Lisboa
Lisboa, Portugal

Dr Sara Irène EYANGOH
Directeur Scientifique, Centre Pasteur du Cameroun
Laboratoire National de Référence et de Santé Publique
Ministère de la Santé Publique
Yaoundé, Cameroon

Professor Subhash HIRA
Professor of Public Health and Senior Advisor
Public Health Foundation of India
New Delhi, India

Professor Mirkuzie Woldie KERIE
Senior Research Adviser (SRA), MCH Directorate
Federal Ministry of Health
Jimma, Ethiopia

Dr Caroline LYNCH
Regional Adviser, Medicines for Malaria Venture
Chiang Mai, Thailand

Professor Catherine (Sassy) MOLYNEUX
Professor in Global Health, Health Systems Research Ethics Department
KEMRI- Wellcome Trust Research Programme
KEMRI Coastal Research Unit
Kilifi, Kenya

Dr Alwyn MWINGA
Executive Director, Zambart
UNZA Ridgeway Campus, Off Nationalist Road
Lusaka, Zambia

Dr Emelda Aluoch OKIRO
Head, Population Health Unit
KEMRI/Wellcome Trust Collaborative Programme
Nairobi, Kenya

Dr Shagufta PERVEEN*
Senior Instructor, Health System and Policy Research Group, Department of Community Health Sciences
The Aga Khan University
Toorak Gardens, SA, Australia

Professor Stephen Bertel SQUIRE
Professor of Clinical Tropical Medicine; Dean of Clinical Sciences and International Public Health
Liverpool School of Tropical Medicine
Liverpool, United Kingdom

* Not able to attend.
Other participants

Special Programme staff

**Director's Office**
- Dr John Reeder, Director
- Dr Garry Aslanyan
- Ms Christine Coze
- Ms Elisabetta Dessi
- Ms Makiko Kitamura
- Ms Mariam Otmani Del Barrio
- Ms Izabela Suder-Dayao
- Mr Robert Terry

**Programme Innovation and Management (PIM)**
- Dr Beatrice Halpaap, Unit Head
- Ms Caroline Easter
- Ms Annabel Francois
- Ms Mary Maier
- Dr Mihai Mihut

**Research for Implementation (IMP)**
- Dr Abraham Aseffa, Unit Head
- Dr Florence Fouque
- Mr Daniel Hollies
- Ms Ekua Johnson
- Dr Mohammed Khogali Ahmed
- Dr Annette Kuesel
- Mr Abdul Masoudi
- Dr Corinne Merle
- Dr Bernadette Ramirez
- Ms Michelle Villasol-Salvador
- Dr Rony Zachariah

**Research Capacity Strengthening (RCS)**
- Dr Dermot Maher, Unit Head
- Ms Najoua Kachouri Aboudi
- Ms Kai Kalmaru
- Dr Edward Kamau
- Dr Pascal Launois
- Dr Mahnaz Vahedi

**TDR Consultants**
- Ms Ana Hernandez Bonilla
- Ms Debora Pedrazzoli
- Dr Marie-Eve Ragenaud
- Ms Vanessa Veronese
- Dr Qingxia Zhong